New drug combo aims to shrink liver tumors before surgery
NCT ID NCT07446257
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 3 times
Summary
This study tests whether giving two drugs (ateganosine and cadonilimab) before surgery can safely shrink liver tumors in people with resectable hepatocellular carcinoma. About 60 participants will receive either one or both drugs before their operation. The main goal is to see if the treatment delays surgery, while also checking how well the tumors respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple immunotherapy cocktail aims to boost surgery success in liver cancer
- Drug cocktail aims to stop liver cancer recurrence after surgery
- New blood test aims to catch liver cancer recurrence early
- New drug combo shows promise in shrinking liver tumors before surgery
- New combo therapy aims to boost liver cancer surgery success
- Liver cancer patients get Pre-Surgery combo: radiation plus immunotherapy shows promise